Q3 EPS Forecast for Oruka Therapeutics Increased by Analyst

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Wedbush upped their Q3 2025 EPS estimates for Oruka Therapeutics in a report issued on Wednesday, September 17th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.42) per share for the quarter, up from their previous forecast of ($0.51). Wedbush currently has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.70) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.89) EPS, FY2027 earnings at ($2.25) EPS, FY2028 earnings at ($2.98) EPS and FY2029 earnings at ($3.71) EPS.

A number of other research analysts also recently issued reports on the company. BTIG Research boosted their price target on Oruka Therapeutics from $44.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of “Buy” and an average target price of $42.00.

Oruka Therapeutics Trading Down 6.2%

Shares of NASDAQ:ORKA opened at $15.55 on Monday. The company has a 50-day moving average price of $14.81 and a 200-day moving average price of $12.22. The company has a market cap of $582.36 million, a price-to-earnings ratio of -5.53 and a beta of -0.26. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.02.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its position in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares in the last quarter. Bank of America Corp DE lifted its position in Oruka Therapeutics by 287.6% during the second quarter. Bank of America Corp DE now owns 18,849 shares of the company’s stock valued at $211,000 after buying an additional 13,986 shares during the period. Cable Car Capital LP boosted its holdings in shares of Oruka Therapeutics by 33.3% during the 2nd quarter. Cable Car Capital LP now owns 600,000 shares of the company’s stock valued at $6,726,000 after buying an additional 150,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at $167,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of Oruka Therapeutics by 22.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the company’s stock worth $591,000 after buying an additional 9,828 shares during the period. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.